Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Arthritis, Rheumatoid 13Spondylitis, Ankylosing 5Colitis, Ulcerative 4Psoriasis 3Crohn Disease 3Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Spondylarthritis 1Sarcoidosis 1Recurrence 1Plaque Psoriasis 1Osteoarthritis 1Nephrotic Syndrome 1Nephrosis, Lipoid 1Mucopolysaccharidosis VI 1Mucopolysaccharidosis II 1Mucopolysaccharidosis I 1Mucopolysaccharidoses 1Melanoma 1Macular dystrophy, corneal type 1 1Kidney Diseases 1Joint Diseases 1Inflammatory Bowel Diseases 1Inflammation 1Hidradenitis Suppurativa 1Healthy Adult Male 1Healthy 1Glomerulosclerosis, Focal Segmental 1Dupuytren Contracture 1Autoimmune Diseases 1

Interventions

Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nephrosis, Lipoid × Adalimumab × Clear all
NCT04009668 2024-10-30

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

University of Michigan

Phase 2 Completed
7 enrolled 12 charts
Genitourinary

Macular dystrophy, corneal type 1, Glomerulosclerosis, Focal Segmental, Kidney Diseases, Nephrosis, Lipoid, Nephrotic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡